Pharmaceuticals company Lincoln Pharmaceuticals announced Q2FY26 results Total Income: Rs 170.60 crore against Rs 171.19 crore during Q2FY25, change -0.34%. EBITDA: Rs 32.66 crore against Rs 38.35 crore during Q2FY25, change -14.86%. PBT: Rs 28.81 crore against Rs 34.78 crore during Q2FY25, change -17.17%. PAT: Rs 20.01 crore against Rs 26.35 crore during Q2FY25, change -24.06%. EPS: Rs 9.98 for Q2FY26. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals, said: "We are pleased to report another strong quarter, reflecting our continued focus on sustainable growth and value creation. With consistent performance across all business verticals, we remain committed to achieving our strategic goal of reaching Rs 1,000 crore in revenue within the next three years. Our growth momentum is supported by expansion into high-value therapeutic segments such as cardiac, diabetic, dermatology, and ENT, along with new product introductions and entry into emerging markets. The commissioning of our Bulk Drug Manufacturing Plant and progress at our Cephalosporin facility further strengthen our backward integration and export capabilities. Supported by our robust R&D;, operational excellence, and a strong product pipeline, we are confident of maintaining 15-18% annual growth. With a debt-free balance sheet, we are well positioned to deliver sustainable, profitable growth and enhance long-term shareholder value." Result PDF